![SWOG Front Line banner](/sites/default/files/styles/news_recent/public/news/2023-02/FrontLineHead.Blanke.2022-web-sized_1.png?itok=A5DWIdBA)
Feb 17, 2023
SWOG recently reported notable results from S1416 in breast cancer and S1815 in biliary tract cancers
![SWOG Front Line banner](/sites/default/files/styles/news_recent/public/news/2023-02/FrontLineHead.Blanke.2022-web-sized_0.png?itok=YOFu0n_c)
Feb 10, 2023
![SWOG Front Line banner](/sites/default/files/styles/news_recent/public/news/2023-02/FrontLineHead.Blanke.2022-web-sized.png?itok=QDpC95_H)
Feb 3, 2023
![S1416 results in Lancet Oncology](/sites/default/files/styles/news_recent/public/news/2023-01/S1416-Sharma-LO-headline-2.png?itok=AScGgltl)
Jan 30, 2023
S1416 trial results show PARP inhibitor benefit in "BRCA-like" triple-negative breast cancer
![SWOG Front Line banner](/sites/default/files/styles/news_recent/public/news/2023-01/FrontLineHead.Blanke.2022-web-sized_2.png?itok=FuR2pdf6)
Jan 27, 2023
![SWOG Front Line banner](/sites/default/files/styles/news_recent/public/news/2023-01/FrontLineHead.Blanke.2022-web-sized_1.png?itok=U19hW5dZ)
Jan 20, 2023
![S1815 results at ASCO GI](/sites/default/files/styles/news_recent/public/news/2023-01/S1815-press-release-card.png?itok=v5JaE_7G)
Jan 20, 2023
Nab-paclitaxel does not extend biliary tract cancer survival, but may benefit some
![SWOG Front Line banner](/sites/default/files/styles/news_recent/public/news/2023-01/FrontLineHead.Blanke.2022-web-sized_0.png?itok=Oc8pLpCL)
Jan 13, 2023
New (and renamed!) – exciting Hope programs with a focus on early-stage investigators
![SWOG Front Line banner](/sites/default/files/styles/news_recent/public/news/2023-01/FrontLineHead.Blanke.2022-web-sized.png?itok=alWlfob3)
Jan 6, 2023